Literature DB >> 27925871

No Signal Intensity Increase in the Dentate Nucleus on Unenhanced T1-weighted MR Images after More than 20 Serial Injections of Macrocyclic Gadolinium-based Contrast Agents.

Alexander Radbruch1, Robert Haase1, Pascal J Kieslich1, Lukas D Weberling1, Philipp Kickingereder1, Wolfgang Wick1, Heinz-Peter Schlemmer1, Martin Bendszus1.   

Abstract

Purpose To determine the effect of more than 20 serial injections of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal intensity (SI) of the dentate nucleus (DN) on unenhanced T1-weighted magnetic resonance (MR) images. Materials and Methods In this retrospective, institutional review board-approved study, 33 patients who underwent at least 20 consecutive MR imaging examinations (plus an additional MR imaging for reference) with the exclusive use of macrocyclic GBCAs gadoterate meglumine and gadobutrol were analyzed. SI ratio differences were calculated for DN-to-pons and DN-to-middle cerebellar peduncle (MCP) ratios by subtracting the SI ratio at the first MR imaging examination from the SI ratio at the last MR imaging examination. One-sample t tests were used to examine if the SI ratio differences differed from 0, and Bayes factors were calculated to quantify the strength of evidence for each test. Results Patients underwent a mean of 23.03 ± (standard deviation) 4.20 GBCA administrations (mean accumulated dose, 491.21 mL ± 87.04 of a 0.5 M GBCA solution) with an average of 12.09 weeks ± 2.16 between every administration. Both ratio differences did not differ significantly from 0 (DN-to-pons ratio: -0.0032 ± 0.0154, P = .248; DN-to-MCP ratio: -0.0011 ± 0.0093, P = .521), and one-sided Bayes factors provided substantial to strong evidence against an SI ratio increase (Bayes factor for DN-to-pons ratio = 0.09 and that for DN-to-MCP ratio = 0.12). Conclusion The study indicates that 20 or more serial injections of macrocyclic GBCAs administered with on average 3 months between each injection are not associated with an SI increase in the DN. © RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27925871     DOI: 10.1148/radiol.2016162241

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  40 in total

Review 1.  Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Authors:  Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2021-04-19

2.  Absence of clinical cerebellar syndrome after serial injections of more than 20 doses of gadoterate, a macrocyclic GBCA: a monocenter retrospective study.

Authors:  Gaetano Perrotta; Thierry Metens; Julie Absil; Marc Lemort; Mario Manto
Journal:  J Neurol       Date:  2017-09-27       Impact factor: 4.849

Review 3.  Distribution and chemical forms of gadolinium in the brain: a review.

Authors:  Tomonori Kanda; Yudai Nakai; Akifumi Hagiwara; Hiroshi Oba; Keiko Toyoda; Shigeru Furui
Journal:  Br J Radiol       Date:  2017-09-28       Impact factor: 3.039

Review 4.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

5.  Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan.

Authors:  Yoshito Tsushima; Kazuo Awai; Gen Shinoda; Hiroyuki Miyoshi; Masayuki Chosa; Toshiyuki Sunaya; Jan Endrikat
Journal:  Jpn J Radiol       Date:  2018-09-19       Impact factor: 2.374

6.  Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).

Authors:  K R Maravilla; D San-Juan; S J Kim; G Elizondo-Riojas; J R Fink; W Escobar; A Bag; D R Roberts; J Hao; C Pitrou; A J Tsiouris; E Herskovits; J B Fiebach
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

7.  Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents.

Authors:  Aida Kiviniemi; Maria Gardberg; Paul Ek; Janek Frantzén; Johan Bobacka; Heikki Minn
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

Review 8.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

9.  Increased variability of watershed areas in patients with high-grade carotid stenosis.

Authors:  Stephan Kaczmarz; Vanessa Griese; Christine Preibisch; Michael Kallmayer; Michael Helle; Isabel Wustrow; Esben Thade Petersen; Hans-Henning Eckstein; Claus Zimmer; Christian Sorg; Jens Göttler
Journal:  Neuroradiology       Date:  2018-01-03       Impact factor: 2.804

Review 10.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.